Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Do we need genotypic weighted resistance scores for antiretrovirals? The curious case of tipranavir.

Antiviral therapy - 1 Jan 2010

Llibre Josep M

Abstract excerpt

Weighted genotypic resistance scores represent a step towards excellence in the interpretation of HIV type-1 (HIV-1) resistance to antiretroviral drugs. They can predict phenotypic resistance and clinical response better than any other unweighted score. With the addition of mutations associated with an increased response and the refinement of the initial weighted score in a different dataset of individuals, the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Antiretroviral Therapy, Highly Active
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Infections

Share to Pyridines

Share to Pyrones

Share to Sulfonamides

Share to Validation Studies as Topic

Source

Identifiers

PMID: 21041910
DOI: 10.3851/IMP1671

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Do we need genotypic weighted resistance scores for antiretrovirals? The curious case of tipranavir.PMID 21041910Read ↗

Improving the prediction of virological response to tipranavir: the development and validation of a tipranavir-weighted mutation score.Semantic proximity Read ↗

Clinical validation and applicability of different tipranavir/ritonavir genotypic scores in HIV-1 protease inhibitor-experienced patients.Semantic proximity Read ↗

Successful virological outcome in an HIV-infected individual with a three-class resistant variant and an insertion in the protease genome with a Tipranavir based regimen.Semantic proximity Read ↗

Comparison of drug resistance scores for tipranavir in protease inhibitor-naive patients infected with HIV-1 B and non-B subtypes.Semantic proximity Read ↗

Scoring methods for building genotypic scores: an application to didanosine resistance in a large derivation set.Semantic proximity Read ↗

Predicting antiretroviral drug resistance from the latest or the cumulative genotype.Semantic proximity Read ↗

An update to the HIV-TRePS system: the development of new computational models that do not require a genotype to predict HIV treatment outcomes.Semantic proximity Read ↗

Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients.Semantic proximity Read ↗

An update to the HIV-TRePS system: the development and evaluation of new global and local computational models to predict HIV treatment outcomes, with or without a genotype.Semantic proximity Read ↗

Changes in darunavir/r resistance score after previous failure to tipranavir/r in HIV-1-infected multidrug-resistant patients.Semantic proximity Read ↗

Selection of antiretroviral therapy guided by genotypic or phenotypic resistance testing: an open-label, randomized, multicenter study (PhenGen).Semantic proximity Read ↗

Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.